about
Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected childrenWhen to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern AfricaThe last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study.Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysisRadiology services for children in HIV- and TB-endemic regions: scope for greater collaboration between radiologists and clinicians caring for children.Tuberculosis and pneumonia in HIV-infected children: an overviewMonitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration.Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.UNSUSPECTED FATAL DRUG-RESISTANT TUBERCULOSIS IN A CLOSELY MONITORED CHILD: A PLEA FOR IMPROVED SOURCE-CASE TRACING AND DRUG SUSCEPTIBILITY TESTINGOutcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration.Viral load versus CD4⁺ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa: a cohort-based modelling studyIncidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort studyUniversal children's day--let's improve current interventions to reduce vertical transmission of HIV nowVirologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.Temporal trends in the characteristics of children at antiretroviral therapy initiation in southern Africa: the IeDEA-SA CollaborationPrognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programsTrends in paediatric bloodstream infections at a South African referral hospital.It is time to consider third-line options in antiretroviral-experienced paediatric patients?Impact of earlier combination antiretroviral therapy on outcomes in children.Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.Outcomes of Infants Starting Antiretroviral Therapy in Southern Africa, 2004-2012.Growth in Virologically Suppressed HIV-Positive Children on Antiretroviral Therapy: Individual and Population-level References.Variability of growth in children starting antiretroviral treatment in southern Africa.Where do HIV-infected adolescents go after transfer? - Tracking transition/transfer of HIV-infected adolescents using linkage of cohort data to a health information system platform.Minimizing the risk of non-vertical, non-sexual HIV infection in children--beyond mother to child transmissionClinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy.Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration.High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.Children with human immunodeficiency virus infection admitted to a paediatric intensive care unit in South Africa.Incidence of AIDS-defining and Other Cancers in HIV-positive Children in South Africa: Record Linkage StudyAccuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa CollaborationThe role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure.Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy.Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children.Reducing CD4 Monitoring in Children on Antiretroviral Therapy With Virologic Suppression.Malaria in children--prevention and management.Infections in HIV-exposed uninfected children with focus on sub-Saharan Africa.Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.Antiretroviral Treatment Initiated in the First Month of Life.
P50
Q26774267-2B8CE804-0B96-46EE-B02F-23EB5A2F24DDQ28535251-14CCECF4-6347-4556-9BB9-431F2BAC73E9Q30382184-2B004DDB-2DC6-45B1-8CEC-093993572EC2Q31039733-AF5E880A-A575-4C7D-B4E0-73D3FEA0CD1FQ33624953-9A8E6286-02EE-43AF-A850-6C0C99C92303Q33754269-0725C5E4-149A-4CF2-B9BB-9AEAF3B6E051Q33801297-EE723FC0-4915-4423-9B93-102C1EDEE0C1Q33830775-65087D7F-882A-4587-8C2F-0FD5958EB8CDQ33926151-75DC95E2-2305-4D37-ADB9-64DE0E61353EQ34058444-58F8048A-3BE8-4257-8856-78F4505EE53BQ34077658-53737A7A-C393-4F25-A556-CF7EF087D448Q34508454-97891650-0B9A-4915-8FE4-E9CE195C6A30Q34508985-085A44C7-FE5F-4220-82DA-CBA67C57FC70Q34558511-D8F18CEF-CE40-45EA-98B4-4AEEDF2117EFQ35014160-83ADD37E-271E-4E60-A405-FF1C620186EBQ35074354-8535221B-900A-49D4-9C54-3CC8B610EF42Q35148237-BBD7CF24-9491-43EF-B6E8-18C69BB8C350Q35404221-073C5038-5C82-4B80-91A6-B86D85B9D8C5Q35586657-9EB35BBC-659E-4517-9DEF-997AD393DB19Q35599081-C6E4AD60-4487-4A73-801C-05F71094651AQ35606554-7419A7F4-558B-42F8-BF70-4FCDD763ECF4Q35872045-D0C5FF76-DD62-475B-AEA1-89E4A8283070Q36062366-37DB9A88-0732-46F8-8259-793E71A30C19Q36277597-814235AA-9A88-4053-8C10-DF8C60045235Q36377427-4FDAAC0D-9E90-4DD1-976A-3F6E909E6BD1Q36405972-AF44DE31-D7D6-4C62-AB66-FFF3964CBAA3Q36465148-4CAEBB77-FF74-4AA0-8F09-244CC22B2B5FQ36565583-F1AE9DF5-7366-4259-950E-5F2642D5F332Q36646867-07532E74-5442-4476-BADA-C67717F586DAQ36831865-9F568716-D3A6-4BF8-9133-1EFF51B51CEBQ36896718-9943B6F1-B82B-4004-88D1-49AE0A8AFB1CQ37199247-CFC1CEDE-7E26-4179-90B8-B17AC72E2769Q37315991-A73388BF-7819-4E08-89A9-7B49A25EA6DCQ37635400-2191F29F-9CAF-4300-A27A-DD3D1BBB5D6AQ37724319-81F4F64A-3508-4F99-9147-7C73E220D532Q37742040-F5ADC437-A0E4-4530-8DD6-84A7808B951BQ38168614-4166287D-475E-4C09-BE16-025D511D6E32Q38237157-ECD9B1F1-83BB-414C-8089-947C62CC62A6Q38874266-40A4B741-D090-4193-8FA4-F0363DBBD487Q39058671-AD5FD295-07C1-48F6-A958-CFDF26CB55FC
P50
name
Helena Rabie
@en
type
label
Helena Rabie
@en
prefLabel
Helena Rabie
@en